Global Measles, Mumps and Rubella (MMR) Vaccines Market - 2021-2028

Global Measles, Mumps and Rubella (MMR) Vaccines Market - 2021-2028

Market Overview

The global measles, mumps, and rubella (MMR) vaccines market size was valued at US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

The MMR vaccine protects against measles, mumps, and rubella. The first dose is usually given to children between the ages of 9 and 15 months, and the second dose is usually given to children between the ages of 15 and 6 years, with at least 4 weeks between doses.

Market Dynamics

The factors driving the global measles, mumps, and rubella (MMR) vaccines are the increasing demand for vaccine and vaccination programs by the government is expected to drive the market growth.

The increasing demand for vaccine and vaccination programs by the government is expected to drive market growth in the forecast period

Vaccine manufacturers are collaborating with organizations such as WHO, UNICEF, and the GAVI Alliance to improve their vaccination programs to reach the greatest number of people with vaccines. Despite several government initiatives, measles remains a leading cause of death among children under five. As a result, increasing the success rate of vaccination programs is dependent on each country's government initiatives. In order to reduce the prevalence of these diseases, some organizations are focusing on initiatives. GAVI Alliances, for instance, has launched a vaccination campaign in high-risk countries such as Afghanistan, Chad, Ethiopia, the Democratic Republic of the Congo, Nigeria, and Pakistan.

Similarly, in 2017, the Government of India launched a Pan-India Measles-Rubella vaccination campaign in which children aged 9 months to 15 years are vaccinated in order to reduce the prevalence of these diseases in children. Such initiatives by various organizations and governments are expected to drive market growth.

The side effects associated with vaccination is expected to hamper the market growth

MMR vaccination can result in a sore arm from the injection or redness where the shot is given, fever, and a mild rash. Swelling of the glands in the cheeks or neck and temporary pain and stiffness in the joints (mostly in adolescent or adult women) can occur following MMR vaccination. Serious reactions are uncommon. These can include seizures (frequently associated with fever) or a temporary low platelet count, resulting in unusual bleeding or bruising. This vaccine may cause a potentially fatal infection in people with compromised immune systems. People who have severe immune system problems should not receive the MMR vaccine.

COVID-19 Impact Analysis

During the COVID-19 pandemic, national and international health agencies advised that immunization services be maintained indefinitely due to the possibility of a resurgence of vaccine-preventable diseases, either controlled or eliminated, as a result of low vaccination coverage. However, studies have shown that, in an attempt to reduce the risk of transmission of SARS-CoV-2, the etiological agent of COVID-19, social isolation measures have reduced vaccination programs in children and adolescents in several countries and regions around the world.

For instance, the MMR vaccine, made from live attenuated measles, rubella, and mumps viruses, is free in Brazil and is recommended for routine vaccination at 12 months and 9 years of age. The historical decrease in MMR vaccine coverage rates in Brazil may have been hampered by sanitary measures implemented in response to the COVID-19 pandemic, the distribution of health services, and the allocation of health resources in Brazil affected by COVID-19.

Segment Analysis

MMR II (measles, mumps, and rubella virus vaccine live) segment is expected to dominate the market growth in the forecast period

M-M-R II is a combination vaccine protecting against measles, mumps, and rubella (MMR). M-M-R II is a sterile lyophilized preparation of ATTENUVAX (Measles Virus Vaccine Live), a more attenuated line of measles virus derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; MUMPSVAX (Mumps Virus Vaccine Live), the Jeryl Lynn (B level) strain of mumps virus propagated in a chick.

Furthermore, M-M-R II comprises weakened strains of live measles, mumps, and rubella viruses. These live virus strains cause either mild or no symptoms of infection. The body responds by producing disease-fighting substances (antibodies) against these infections when the vaccine is given. When a vaccinated child comes into contact with the measles, mumps, or rubella virus, the body is usually ready to destroy it and produces antibodies. However, as with all vaccines, there is no guarantee of complete protection against measles, mumps, and rubella. Furthermore, maximum protection may take up to 4-6 weeks to develop so that infections may occur during this time.

Geographical Analysis

North America region is expected to hold the largest market share in the global measles, mumps, and rubella (MMR) vaccines market

The growing prevalence of measles, mumps, and rubella and the increasing government vaccination programs in this region are expected to drive the market growth.

In the United States, 371 cases of measles were confirmed in 2018. The Centers for Disease Control and Prevention (CDC) confirmed 1215 cases across 30 states from January to August 2019. In conjunction with mass immunization campaigns in countries with high case and death rates, routine measles vaccination for children is a critical public health strategy for reducing global measles deaths. For nearly 60 years, the measles vaccine has been in use. It is risk-free, efficient, and inexpensive. A child's immunization against measles costs about one dollar in the United States. The availability of vaccines in this region is expected to boost market growth. For instance, in the United States, two vaccines containing the measles, mumps, and rubella virus are approved for use. The M-M-R II vaccine protects against measles, mumps, and rubella (MMR). ProQuad is a vaccine that protects against measles, mumps, rubella, and varicella (MMRV).

Competitive Landscape

The global measles, mumps, and rubella (MMR) vaccines market are moderately competitive, increasing company collaborations, clinical trials, acquisitions, and product launches. Some of the key players in the market are GlaxoSmithKline plc, Merck & Co. Inc. and Serum Institute of India Ltd, Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited.

GlaxoSmithKline plc

Overview: GlaxoSmithKline is a science-led global healthcare company. It is the world’s largest vaccines company by revenue, delivering vaccines that help protect people at all stages of life. GlaxoSmithKline pharmaceuticals have a broad portfolio of innovative and established HIV, respiratory, immuno-inflammation, and oncology medicines. The company was founded in 2000.

Product Portfolio: Priorix is a lyophilized mixture of the attenuated viruses Schwarz measles, RIT 4385 mumps (derived from the Jeryl Lynn strain), and Wistar RA 27/3 rubella. The vaccine's measles and mumps components are made in chick embryo cell culture and may contain traces of egg protein. It is indicated to protect against measles, mumps, and rubella.

Key Developments: On August 2nd, 2021, GlaxoSmithKline submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for its Priorix vaccine, seeking approval for use in active immunization against measles, mumps, and rubella infection (MMR). If approved, the Priorrix vaccine would provide an alternative MMR vaccine to healthcare providers in the United States.

Why Purchase the Report?
Visualize the composition of the global measles, mumps, and rubella (MMR) vaccines market segmentation by type and end user, highlighting the key commercial assets and players.
Identify commercial opportunities in the global measles, mumps and rubella (MMR) vaccines market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of global measles, mumps and rubella (MMR) vaccines market- level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players

The global measles, mumps and rubella (MMR) vaccines market report would provide an access to an approx. 45+market data table, 40+ figures and 180 pages.

Target Audience
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Research Professionals
Emerging Companies
Manufacturers

Market Segmentation

Global Measles, Mumps and Rubella (MMR) Vaccines Market- By Type
MMR

o M-M-R II
MMRV

o ProQuad
Others

Global Measles, Mumps and Rubella (MMR) Vaccines Market- By End User
Hospitals
Clinics
Vaccination Centre
Others

Global Measles, Mumps and Rubella (MMR) Vaccines Market- By Region
North America
Europe
South America
Asia Pacific
Middle East and Africa